Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
Martin JäderstenKsenia BoriskinaCarolin LindholmSimone WeströmLucia CavelierEva Hellström-LindbergStephan MielkeMagnus TobiassonPublished in: Leukemia & lymphoma (2021)